tetano
Editor, Senior Moderator
Virology. 2014 Dec 26;476C:189-195. doi: 10.1016/j.virol.2014.12.017. [Epub ahead of print]
[h=1]Lactococcus lactis displayed neuraminidase confers cross protective immunity against influenza A viruses in mice.[/h] Lei H[SUP]1[/SUP], Peng X[SUP]2[/SUP], Zhao D[SUP]2[/SUP], Ouyang J[SUP]2[/SUP], Jiao H[SUP]2[/SUP], Shu H[SUP]2[/SUP], Ge X[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A viruses pose a serious threat to public health. Current influenza A vaccines predominantly focus on hemagglutinin (HA) and show strain-specific protection. Neuraminidase (NA) is much less studied in the context of humoral immunity against influenza A viruses. The purpose of this study is to evaluate the cross protective immunity of NA presented on Lactococcus lactis (L.lactis) surface against homologous and heterologous influenza A viruses in the mouse model. L.lactis/pNZ8110-pgsA-NA was constructed in which pgsA was used as an anchor protein. Mice vaccinated orally with L.lactis/pNZ8110-pgsA-NA could elicit significant NA-specific serum IgG and mucosa IgA antibodies, as well as neuraminidase inhibition (NI) titers. Importantly, L.lactis/pNZ8110-pgsA-NA provided 80% protection against H5N1, 60% protection against H3N2 and H1N1, respectively. These findings suggest that recombinant L.lactis/pNZ110-pgsA-NA in the absence of adjuvant via oral administration can be served as an effective vaccine candidate against diverse strains of influenza A viruses.
Copyright ? 2014 Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] Cross protective immunity; L.lactis/pNZ8110-pgsA-NA; Neuraminidase (NA)
PMID: 25546254 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25546254
[h=1]Lactococcus lactis displayed neuraminidase confers cross protective immunity against influenza A viruses in mice.[/h] Lei H[SUP]1[/SUP], Peng X[SUP]2[/SUP], Zhao D[SUP]2[/SUP], Ouyang J[SUP]2[/SUP], Jiao H[SUP]2[/SUP], Shu H[SUP]2[/SUP], Ge X[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A viruses pose a serious threat to public health. Current influenza A vaccines predominantly focus on hemagglutinin (HA) and show strain-specific protection. Neuraminidase (NA) is much less studied in the context of humoral immunity against influenza A viruses. The purpose of this study is to evaluate the cross protective immunity of NA presented on Lactococcus lactis (L.lactis) surface against homologous and heterologous influenza A viruses in the mouse model. L.lactis/pNZ8110-pgsA-NA was constructed in which pgsA was used as an anchor protein. Mice vaccinated orally with L.lactis/pNZ8110-pgsA-NA could elicit significant NA-specific serum IgG and mucosa IgA antibodies, as well as neuraminidase inhibition (NI) titers. Importantly, L.lactis/pNZ8110-pgsA-NA provided 80% protection against H5N1, 60% protection against H3N2 and H1N1, respectively. These findings suggest that recombinant L.lactis/pNZ110-pgsA-NA in the absence of adjuvant via oral administration can be served as an effective vaccine candidate against diverse strains of influenza A viruses.
Copyright ? 2014 Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] Cross protective immunity; L.lactis/pNZ8110-pgsA-NA; Neuraminidase (NA)
PMID: 25546254 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25546254